APO Research
Talk to an analyst

APO RESEARCH · REPORT

Diabetic Gastroparesis Treatment

Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that diabetes causes.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that diabetes causes.

During normal digestion, the stomach contracts to help break down food and move it into the small intestine. Gastroparesis disrupts the stomach’s contraction, which can interrupt digestion. Diabetes can cause gastroparesis due to its effects on the nervous system.

Both type 1 diabetes and type 2 diabetes can cause nerve damage. One of the nerves diabetes may damage is the vagus nerve. The vagus nerve controls the movement of food through the stomach. When the vagus nerve experiences damage, the muscles in the stomach and other parts of the digestive tract are not able to function properly. When this happens, food cannot move as quickly through the digestive system. Gastroparesis is also known as delayed gastric emptying.

Selected research

Market Outlook & Growth Opportunities

Global Diabetic Gastroparesis Treatment Market Outlook and Growth Opportunities 2026

28 December 2025192 pages

Choose your research edition.

Industry ResearchDiabetic Gastroparesis Treatment Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Diabetic Gastroparesis Treatment Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Diabetic Gastroparesis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diabetic Gastroparesis Treatment Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Diabetic Gastroparesis Treatment Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that diabetes causes.

During normal digestion, the stomach contracts to help break down food and move it into the small intestine. Gastroparesis disrupts the stomach’s contraction, which can interrupt digestion. Diabetes can cause gastroparesis due to its effects on the nervous system.

Both type 1 diabetes and type 2 diabetes can cause nerve damage. One of the nerves diabetes may damage is the vagus nerve. The vagus nerve controls the movement of food through the stomach. When the vagus nerve experiences damage, the muscles in the stomach and other parts of the digestive tract are not able to function properly. When this happens, food cannot move as quickly through the digestive system. Gastroparesis is also known as delayed gastric emptying.

Read the full market overview

Market is not concentrated. Sumitomo, Johnson & Johnson, Sanofi are the leaders of the industry, and hold the key technologies and patent, with high-end customers. Top 3 manufacturer accounted for 7.4% market share in 2019.

This report provides an overview of the global Diabetic Gastroparesis Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Diabetic Gastroparesis Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Diabetic Gastroparesis Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Diabetic Gastroparesis Treatment market.

Diabetic Gastroparesis Treatment Segment by Company

Sumitomo

Johnson & Johnson

Sanofi

Medtronic

Pfizer

Teva

Boston Scientific

Diabetic Gastroparesis Treatment Segment by Type

Drugs

Surgical Treatment Products

Diabetic Gastroparesis Treatment Segment by Application

Hospital Pharmacies

Private Clinics

Drug Stores

E-Commerce

Diabetic Gastroparesis Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Diabetic Gastroparesis Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Diabetic Gastroparesis Treatment key companies, revenue, market share, and recent developments.

3. To split the Diabetic Gastroparesis Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Diabetic Gastroparesis Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Diabetic Gastroparesis Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Diabetic Gastroparesis Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetic Gastroparesis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diabetic Gastroparesis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetic Gastroparesis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Diabetic Gastroparesis Treatment industry.

Chapter 3: Detailed analysis of Diabetic Gastroparesis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Diabetic Gastroparesis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Diabetic Gastroparesis Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Diabetic Gastroparesis Treatment Industry Trends Table 2. Diabetic Gastroparesis Treatment Industry Drivers Table 3. Diabetic Gastroparesis Treatment Industry Opportunities and Challenges Table 4. Diabetic Gastroparesis Treatment Industry Restraints Table 5. Global Diabetic Gastroparesis Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Diabetic Gastroparesis Treatment Revenue Share by Company (2021-2026) Table 7. Global Diabetic Gastroparesis Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Diabetic Gastroparesis Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Diabetic Gastroparesis Treatment Company, Product Type & Application Table 10. Global Diabetic Gastroparesis Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Diabetic Gastroparesis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Drugs Table 15. Significant Companies of Surgical Treatment Products Table 16. Global Diabetic Gastroparesis Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Diabetic Gastroparesis Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Diabetic Gastroparesis Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Diabetic Gastroparesis Treatment Sales Value Share by Type (2021-2026) Table 20. Global Diabetic Gastroparesis Treatment Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Pharmacies Table 22. Significant Companies of Private Clinics Table 23. Significant Companies of Drug Stores Table 24. Significant Companies of E-Commerce Table 25. Global Diabetic Gastroparesis Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Diabetic Gastroparesis Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Diabetic Gastroparesis Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Diabetic Gastroparesis Treatment Sales Value Share by Application (2021-2026) Table 29. Global Diabetic Gastroparesis Treatment Sales Value Share by Application (2027-2032) Table 30. Global Diabetic Gastroparesis Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Diabetic Gastroparesis Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Diabetic Gastroparesis Treatment Sales Value Share by Region (2021-2026) Table 33. Global Diabetic Gastroparesis Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Diabetic Gastroparesis Treatment Sales Value Share by Region (2027-2032) Table 35. Global Diabetic Gastroparesis Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Diabetic Gastroparesis Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Diabetic Gastroparesis Treatment Sales Value Market Share by Country (2021-2026) Table 38. Global Diabetic Gastroparesis Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Diabetic Gastroparesis Treatment Sales Value Market Share by Country (2027-2032) Table 40. Sumitomo Company Information Table 41. Sumitomo Business Overview Table 42. Sumitomo Diabetic Gastroparesis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Sumitomo Diabetic Gastroparesis Treatment Product Portfolio Table 44. Sumitomo Recent Development Table 45. Johnson & Johnson Company Information Table 46. Johnson & Johnson Business Overview Table 47. Johnson & Johnson Diabetic Gastroparesis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Johnson & Johnson Diabetic Gastroparesis Treatment Product Portfolio Table 49. Johnson & Johnson Recent Development Table 50. Sanofi Company Information Table 51. Sanofi Business Overview Table 52. Sanofi Diabetic Gastroparesis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Sanofi Diabetic Gastroparesis Treatment Product Portfolio Table 54. Sanofi Recent Development Table 55. Medtronic Company Information Table 56. Medtronic Business Overview Table 57. Medtronic Diabetic Gastroparesis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Medtronic Diabetic Gastroparesis Treatment Product Portfolio Table 59. Medtronic Recent Development Table 60. Pfizer Company Information Table 61. Pfizer Business Overview Table 62. Pfizer Diabetic Gastroparesis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Pfizer Diabetic Gastroparesis Treatment Product Portfolio Table 64. Pfizer Recent Development Table 65. Teva Company Information Table 66. Teva Business Overview Table 67. Teva Diabetic Gastroparesis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Teva Diabetic Gastroparesis Treatment Product Portfolio Table 69. Teva Recent Development Table 70. Boston Scientific Company Information Table 71. Boston Scientific Business Overview Table 72. Boston Scientific Diabetic Gastroparesis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Boston Scientific Diabetic Gastroparesis Treatment Product Portfolio Table 74. Boston Scientific Recent Development Table 75. Research Programs/Design for This Report Table 76. Authors List of This Report Table 77. Secondary Sources Table 78. Primary Sources List of Figures Figure 1. Diabetic Gastroparesis Treatment Product Image Figure 2. Global Diabetic Gastroparesis Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diabetic Gastroparesis Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Diabetic Gastroparesis Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Drugs Image Figure 8. Surgical Treatment Products Image Figure 9. Global Diabetic Gastroparesis Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Diabetic Gastroparesis Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Diabetic Gastroparesis Treatment Sales Value Share by Type (2021-2032) Figure 12. Hospital Pharmacies Image Figure 13. Private Clinics Image Figure 14. Drug Stores Image Figure 15. E-Commerce Image Figure 16. Global Diabetic Gastroparesis Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Diabetic Gastroparesis Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Diabetic Gastroparesis Treatment Sales Value Share by Application (2021-2032) Figure 19. Global Diabetic Gastroparesis Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Diabetic Gastroparesis Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Diabetic Gastroparesis Treatment Sales Value (2021-2032) & (US$ Million) Figure 22. North America Diabetic Gastroparesis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Diabetic Gastroparesis Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Diabetic Gastroparesis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Diabetic Gastroparesis Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Diabetic Gastroparesis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Diabetic Gastroparesis Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. South America Diabetic Gastroparesis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Diabetic Gastroparesis Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Diabetic Gastroparesis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Drugs
  • Surgical Treatment Products
Applications
  • Hospital Pharmacies
  • Private Clinics
  • Drug Stores
  • E-Commerce
Companies covered
  • Sumitomo
  • Johnson & Johnson
  • Sanofi
  • Medtronic
  • Pfizer
  • Teva
  • Boston Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Diabetic Gastroparesis Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Diabetic Gastroparesis Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Diabetic Gastroparesis Treatment Market Dynamics
  1. 2.1 Diabetic Gastroparesis Treatment Industry Trends
  2. 2.2 Diabetic Gastroparesis Treatment Industry Drivers
  3. 2.3 Diabetic Gastroparesis Treatment Industry Opportunities and Challenges
  4. 2.4 Diabetic Gastroparesis Treatment Industry Restraints
3 Diabetic Gastroparesis Treatment Market by Company
  1. 3.1 Global Diabetic Gastroparesis Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Diabetic Gastroparesis Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Diabetic Gastroparesis Treatment Company Ranking (2024-2026)
  4. 3.4 Global Diabetic Gastroparesis Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Diabetic Gastroparesis Treatment Company Product Type and Application
  6. 3.6 Global Diabetic Gastroparesis Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Diabetic Gastroparesis Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Diabetic Gastroparesis Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Diabetic Gastroparesis Treatment Market by Type
  1. 4.1 Diabetic Gastroparesis Treatment Type Introduction
  2. 4.1.1 Drugs
  3. 4.1.2 Surgical Treatment Products
  4. 4.2 Global Diabetic Gastroparesis Treatment Sales Value by Type
  5. 4.2.1 Global Diabetic Gastroparesis Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Diabetic Gastroparesis Treatment Sales Value by Type (2021-2032)
  7. 4.2.3 Global Diabetic Gastroparesis Treatment Sales Value Share by Type (2021-2032)
5 Diabetic Gastroparesis Treatment Market by Application
  1. 5.1 Diabetic Gastroparesis Treatment Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Private Clinics
  4. 5.1.3 Drug Stores
  5. 5.1.4 E-Commerce
  6. 5.2 Global Diabetic Gastroparesis Treatment Sales Value by Application
  7. 5.2.1 Global Diabetic Gastroparesis Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Diabetic Gastroparesis Treatment Sales Value by Application (2021-2032)
  9. 5.2.3 Global Diabetic Gastroparesis Treatment Sales Value Share by Application (2021-2032)
6 Diabetic Gastroparesis Treatment Regional Value Analysis
  1. 6.1 Global Diabetic Gastroparesis Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Diabetic Gastroparesis Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Diabetic Gastroparesis Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Diabetic Gastroparesis Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Diabetic Gastroparesis Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Diabetic Gastroparesis Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Diabetic Gastroparesis Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Diabetic Gastroparesis Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Diabetic Gastroparesis Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Diabetic Gastroparesis Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Diabetic Gastroparesis Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Diabetic Gastroparesis Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Diabetic Gastroparesis Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Diabetic Gastroparesis Treatment Sales Value Share by Country, 2025 VS 2032
7 Diabetic Gastroparesis Treatment Country-level Value Analysis
  1. 7.1 Global Diabetic Gastroparesis Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Diabetic Gastroparesis Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Diabetic Gastroparesis Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Diabetic Gastroparesis Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Diabetic Gastroparesis Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Diabetic Gastroparesis Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Diabetic Gastroparesis Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sumitomo
  2. 8.1.1 Sumitomo Company Information
  3. 8.1.2 Sumitomo Business Overview
  4. 8.1.3 Sumitomo Diabetic Gastroparesis Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sumitomo Diabetic Gastroparesis Treatment Product Portfolio
  6. 8.1.5 Sumitomo Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Diabetic Gastroparesis Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Diabetic Gastroparesis Treatment Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Diabetic Gastroparesis Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Diabetic Gastroparesis Treatment Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Medtronic
  20. 8.4.1 Medtronic Company Information
  21. 8.4.2 Medtronic Business Overview
  22. 8.4.3 Medtronic Diabetic Gastroparesis Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Medtronic Diabetic Gastroparesis Treatment Product Portfolio
  24. 8.4.5 Medtronic Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Diabetic Gastroparesis Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Diabetic Gastroparesis Treatment Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Teva
  32. 8.6.1 Teva Company Information
  33. 8.6.2 Teva Business Overview
  34. 8.6.3 Teva Diabetic Gastroparesis Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Teva Diabetic Gastroparesis Treatment Product Portfolio
  36. 8.6.5 Teva Recent Developments
  37. 8.7 Boston Scientific
  38. 8.7.1 Boston Scientific Company Information
  39. 8.7.2 Boston Scientific Business Overview
  40. 8.7.3 Boston Scientific Diabetic Gastroparesis Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Boston Scientific Diabetic Gastroparesis Treatment Product Portfolio
  42. 8.7.5 Boston Scientific Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst